About Pandorum
Pandorum is a company based in Bengaluru (India) founded in 2011 by Tuhin Bhowmick and Arun Chandru. Pandorum has raised $49.92 million across 16 funding rounds from investors including Kotak Mahindra Bank, We Founder Circle and 021 Capital. The company has 27 employees. Pandorum offers products and services including Bioengineered Cornea, Mini Liver, Lung Regeneration, and Technology Platform. Pandorum operates in a competitive market with competitors including Ensoma, Avita Medical, Newcells Biotech, Organogenesis and InSphero, among others.
- Headquarter Bengaluru, India
- Employees 27
- Founders Tuhin Bhowmick, Arun Chandru
- Stage Minicorn
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website pandorum.com
- Social LinkedIn Facebook
- Legal Name Pandorum Technologies Private Limited
- Date of Incorporation 16 May, 2011
- Jurisdiction Bengaluru, Karnataka, India
- Annual Revenue₹3.53 Cr
FY 2025 · +322% YoY
- Net Loss-₹29.07 Cr
FY 2025 · -825% margin
- EBITDA-₹27.71 Cr
FY 2025 · -786% margin
- Total Equity Funding$49.92M (USD)
in 16 rounds
- Latest Funding Round$429.41K (USD), Series B
Mar 2026
- InvestorsKotak Mahindra Bank
& 70 more
- Employee Count27
Associated legal entities of Pandorum
Pandorum operates through Pandorum Technologies Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Pandorum Technologies Private Limited CIN U72200KA2011PTC058650 | Active | 16 May 2011 | Bengaluru, Karnataka | ₹3.5 Cr | 27 | 6 | View details |
Products & Services of Pandorum
Pandorum offers a comprehensive portfolio of products and services, including Bioengineered Cornea, Mini Liver, Lung Regeneration, and Technology Platform.
Treats corneal disorders through regenerative tissue therapy
Supports drug discovery using human liver organoids
Repairs lung damage via exosomal therapy
Enables tissue fabrication for research applications
Funding Insights of Pandorum
Pandorum has successfully raised a total of $49.92M across 16 strategic funding rounds. The most recent funding activity was a Series B round of $429.41 thousand completed in March 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $49.92M
- Total Rounds 16
- Last Round Series B — $429,407
- Investors Count 71
Latest 10 of 16 funding rounds of Pandorum with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2026 | $429,407 | Series B | – | – | |
| Jan 2026 | $664,229 | Series B | – | – | |
| Nov 2025 | $10M | Series B | – | – | |
| Jan 2024 | $2.01M | Series A | – | – | |
| Aug 2023 | $11M | Series A | $40.67M | Ashish Kacholia | |
| Aug 2023 | $1.56M | Series A | – | We Founder Circle | – |
| Oct 2021 | $4.8M | Series A | – | Sunil Kant Munjal | – |
| Jun 2021 | $54,073 | Series A | $42.87M | Priyank Shankar Garg | |
| Sep 2020 | $5.63M | Series A | $••••• | BTB Venture, 021 Capital | |
| Sep 2020 | $5.63M | Series A | – | – |
| Date | Valuation | Stage |
|---|---|---|
| Aug 2023 | $40.67M | •••••••• |
| Jun 2021 | $42.87M | •••••••• |
| Sep 2020 | $••••• | •••••••• |
| Dec 2017 | $••••• | •••••••• |
| Apr 2016 | $••••• | •••••••• |
Full valuation and stage history of Pandorum
Every valuation point, the growth-stage changes (minicorn, soonicorn, unicorn) and the dates behind them require an active premium plan.
- All valuation points
- Stage changes
- Dates
- Exports
Verified entity values are shown only after access is granted.
Last known valuation $40.67M (Aug 2023). 71 investors in total: 20 institutional and 51 angel.
Investors in Pandorum
Pandorum has secured backing from 71 investors, including angel, venture fund, and institutional investors. Prominent investors backing the company include Kotak Mahindra Bank, We Founder Circle and 021 Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Angel investor network investing in early-stage startups | – | iangroup.vc | Delhi, India | |
- | – | everestfinanceandinvestmentcompany.tcc.mode | - | |
Investment in early-stage startups and global community support. | 2020 | wefoundercircle.com | Mumbai, India | |
Venture capital fund backed by government financial institutions focused on early and growth stage startups | 1999 | kitven.in | Bengaluru, India | |
Early-stage venture capital investment firm | – | xeed.vc | Bengaluru, India | |
Venture capital and acceleration are provided to tech startups. | – | 500.co | Ho Chi Minh City, Vietnam | |
- | – | acebrightpharma.tcc.mode | - | |
- | – | equipactadvisory.tcc.mode | - | |
Investment and financial consulting services are provided in Delhi, India. | – | bflinvestmentsandfinancialconsultants.tcc.mode | Delhi, India | |
Supplier of pressure and temperature instrumentation products | 2007 | apollotradingcompany.com | Tiruchirappalli, India |
Investor details for Pandorum
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Pandorum Technologies Private Limited (Pandorum)
Pandorum Technologies Private Limited is the primary company behind Pandorum. The board of Pandorum Technologies Private Limited currently have 6 directors; the longest-serving is Arun Chandru Raja, appointed in 2011. 2 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Arun Chandru Raja DIN 03474748 | Director | 16 May 2011 | 15 yrs 4 mo | Pandorum Technologies Private Limited |
| Tuhin Bhowmick DIN 03474756 | Director | 16 May 2011 | 15 yrs 4 mo | Pandorum Technologies Private Limited |
| Sonal Asthana DIN 07073986 | Director | 14 Nov 2016 | 9 yrs 10 mo | Pandorum Technologies Private Limited |
| Manish Kumar Belmannu DIN 00324519 | Nominee Director | 18 Jul 2018 | 8 yrs 2 mo | Pandorum Technologies Private Limited |
| Sailesh Tulshan DIN 07309300 | Director | 10 Aug 2018 | 8 yrs 1 mo | Pandorum Technologies Private Limited |
| Sudipta Gautam DIN 02896765 | Nominee Director | 18 Dec 2019 | 6 yrs 9 mo | Pandorum Technologies Private Limited |
People of Pandorum
2 people are tracked at Pandorum (2 in leadership); the tracked headcount is 27.
| Name | Role | Group |
|---|---|---|
| Co-Founder & CEO & Director | Leadership | |
| Co-Founder& CTO & Director | Leadership |
Complete people profiles for Pandorum
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of Pandorum
Figures of Pandorum Technologies Private Limited, the primary company behind Pandorum, for FY 2025. Revenue was ₹3.53 Cr (+322% year on year). Net loss was -₹29.07 Cr (-825% margin). EBITDA was -₹27.71 Cr (-786% margin). Revenue has grown at a compounded annual rate of +76% over three years and +54% over five years.
- ₹3.53 CrRevenue · FY 2025 · +322% YoY
- -₹29.07 CrNet loss · -825% margin
- -₹27.71 CrEBITDA · -786% margin
- ₹4.68 CrPaid-up capital
- 27Employees (provident fund records)
- +76%Revenue CAGR, 3 years
- +54%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Pandorum Technologies Private Limited are on its company page.
Detailed financial statements for Pandorum
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Pandorum
4 dated milestones of Pandorum across 15 years, from founding to its latest funding, stage changes and deals.
- Founded Pandorum is founded.
- Funding First funding round.
- Milestone Reaches Minicorn status.
- Funding Latest funding round, Series B, of $429K.
Competitors of Pandorum
Pandorum operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Ensoma, Avita Medical, Newcells Biotech, Organogenesis and InSphero, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| ensoma.com | 2019 | Boston, United States | $205M | 52 | Provider of in vivo stem cell modification technologies and vector-based drug delivery tool | |
| avitamedical.com | 1992 | Cambridge, United Kingdom | – | 108 | Products for regenerative and respiratory medicine are developed and distributed. | |
| newcellsbiotech.co.uk | 2014 | Newcastle Upon Tyne, United Kingdom | $14.43M | 22 | Induced pluripotent stem cell-derived organoid models are developed for research. | |
| organogenesis.com | 1985 | Canton, United States | $30M | 856 | Regenerative therapies for wound care are developed and commercialized. | |
| insphero.com | 2009 | Schlieren, Switzerland | $35.02M | – | Cell-based assays and 3D microtissues for drug screening are developed. | |
| treefrog.fr | 2018 | Talence, France | $84.25M | – | Developer of stem cells and organoids using proprietary technology | |
| orthofix.com | 1980 | Lewisville, United States | – | 1,634 | Reconstructive and regenerative solutions for bone conditions are developed. | |
| histogenics.com | 2000 | Waltham, United States | $115.72M | 69 | Restorative cell therapies for orthopedic diseases are developed. | |
| rokithealthcare.com | 2012 | Seoul, South Korea | $9.85M | – | 4D bio-printer solutions for tissue regeneration are provided. |
Detailed competitors of Pandorum
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Pandorum
The website of Pandorum (pandorum.com) receives about 5K visits a month.
- Monthly visits5K
▼ 4.1% vs previous month
Websites whose visitors overlap most with Pandorum. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
sciencegurus.org | sciencegurus.org | 100% | – | #4,908,963 | – |
Latest news on Pandorum
Complete news archive for Pandorum
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Pandorum
10 companies that operate in the same segment as Pandorum (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | – | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Pandorum
Pandorum was founded in 2011 and raised its 1st funding round 1 year after it was founded.
Pandorum is headquartered in Bengaluru, India. It is registered at Bengaluru, Karnataka, India.
Tuhin Bhowmick is the current CEO of Pandorum. They have also founded this company.
Pandorum is a funded company, having raised a total of $49.92M across 16 funding rounds to date. The company's 1st funding round was a Series A of $5.63M, raised on Jun 2012.
Pandorum has 27 employees.
The primary company behind Pandorum, Pandorum Technologies Private Limited, reported revenue of ₹3.53 Cr for FY 2025, up 322% year on year.
Pandorum was founded in 2011 in Bengaluru, India, within the biotechnology sector. Focus is placed on regenerative medicine through 3D printing and fabrication techniques. Products developed include a bioengineered cornea hydrogel for treating blindness, 3D hepatocyte spheroids for drug discovery and liver therapies, and exosome-based cell-free treatments for lung regeneration. Operations center on advancing tissue engineering solutions.
Pandorum's top competitors include Avita Medical, Newcells Biotech and InSphero.
Pandorum offers Bioengineered Cornea, Mini Liver, Lung Regeneration, and Technology Platform.
Pandorum has 71 investors. Key investors include Kotak Mahindra Bank, We Founder Circle, 021 Capital, KITVEN, and BTB Venture.
The valuation of Pandorum is $40.67M as of Aug 2023.
Pandorum operates through Pandorum Technologies Private Limited.